New therapies in the management of hepatitis C virus
- PMID: 20224396
- DOI: 10.1097/MOG.0b013e3283383c8f
New therapies in the management of hepatitis C virus
Abstract
Purpose of review: The present review discusses recent developments in drug discovery for hepatitis C. We are on the verge of a new era with the introduction of direct acting oral agents that will transform the treatment landscape. Both healthcare providers and patients need to stay abreast of these changes that will influence decisions to treat. This article will discuss the most promising up-to-date hepatitis C virus antiviral therapies in clinical investigation as well as the associated clinical trial results.
Recent findings: First generation protease inhibitors will offer higher sustained viral response rates for both naive (70-80%) and treatment-experienced (40-50%) populations when added to standard pegylated interferon and ribavirin. However, these dramatic gains will be partially offset by new challenges with viral resistance and increased adverse events.
Summary: There are currently a number of drugs under investigation that target the enzymes involved in hepatitis C virus replication. Year 2011 should bring the approval of the first generation of protease inhibitors that will offer higher cure rates for genotype 1 patients and open the door for the eventual testing of interferon-free regimens.
Similar articles
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
New therapeutic options for hepatitis C.Curr Opin Infect Dis. 2006 Dec;19(6):615-22. doi: 10.1097/QCO.0b013e328010a869. Curr Opin Infect Dis. 2006. PMID: 17075339 Review.
-
Novel interferons for treatment of hepatitis C virus.Clin Liver Dis. 2009 Aug;13(3):351-63. doi: 10.1016/j.cld.2009.05.004. Clin Liver Dis. 2009. PMID: 19628153 Review.
-
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.Aliment Pharmacol Ther. 2006 Aug 15;24(4):593-600. doi: 10.1111/j.1365-2036.2006.03018.x. Aliment Pharmacol Ther. 2006. PMID: 16907892
-
Management of hepatitis C virus genotype 4.J Gastroenterol Hepatol. 2004 Nov;19(11):1233-9. doi: 10.1111/j.1440-1746.2003.03325.x. J Gastroenterol Hepatol. 2004. PMID: 15482528 Review.
Cited by
-
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD008516. doi: 10.1002/14651858.CD008516.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972122 Free PMC article. Review.
-
Exploring the possibility of an interferon-free treatment regimen for hepatitis C virus infection.Gastroenterol Hepatol (N Y). 2011 Mar;7(3):185-7. Gastroenterol Hepatol (N Y). 2011. PMID: 21528046 Free PMC article. No abstract available.
-
A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus.J Virol. 2011 Dec;85(23):12351-61. doi: 10.1128/JVI.05313-11. Epub 2011 Sep 28. J Virol. 2011. PMID: 21957313 Free PMC article.
-
Efficient palliative involved-field radiotherapy on highly progressive diffuse large B-cell primary gastric lymphoma with liver cirrhosis.Clin J Gastroenterol. 2012 Apr;5(2):164-9. doi: 10.1007/s12328-012-0292-7. Epub 2012 Mar 11. Clin J Gastroenterol. 2012. PMID: 26182162
-
Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus.PLoS One. 2013 May 21;8(5):e64449. doi: 10.1371/journal.pone.0064449. Print 2013. PLoS One. 2013. PMID: 23700478 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
